Scancell Holdings Plc Stock Net Income
| SCNLF Stock | USD 0.19 0.05 35.71% |
As of the 9th of February, Scancell Holdings has the Coefficient Of Variation of 607.64, variance of 23.26, and Risk Adjusted Performance of 0.1409. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Scancell Holdings plc, as well as the relationship between them. Please validate Scancell Holdings plc mean deviation, total risk alpha, as well as the relationship between the Total Risk Alpha and kurtosis to decide if Scancell Holdings is priced more or less accurately, providing market reflects its prevalent price of 0.19 per share. As Scancell Holdings plc appears to be a penny stock we also recommend to double-check its information ratio numbers.
Scancell Holdings' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Scancell Holdings' valuation are provided below:Scancell Holdings plc does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Scancell |
Scancell Holdings 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Scancell Holdings' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Scancell Holdings.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Scancell Holdings on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Scancell Holdings plc or generate 0.0% return on investment in Scancell Holdings over 90 days. Scancell Holdings is related to or competes with Innate Pharma, NDT Pharmaceuticals, Molecular Partners, Brii Biosciences, Hofseth BioCare, Kintor Pharmaceutical, and NervGen Pharma. Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vac... More
Scancell Holdings Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Scancell Holdings' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Scancell Holdings plc upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.146 | |||
| Maximum Drawdown | 35.71 |
Scancell Holdings Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Scancell Holdings' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Scancell Holdings' standard deviation. In reality, there are many statistical measures that can use Scancell Holdings historical prices to predict the future Scancell Holdings' volatility.| Risk Adjusted Performance | 0.1409 | |||
| Jensen Alpha | 0.802 | |||
| Total Risk Alpha | 0.3068 | |||
| Treynor Ratio | (3.40) |
Scancell Holdings February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1409 | |||
| Market Risk Adjusted Performance | (3.39) | |||
| Mean Deviation | 1.54 | |||
| Coefficient Of Variation | 607.64 | |||
| Standard Deviation | 4.82 | |||
| Variance | 23.26 | |||
| Information Ratio | 0.146 | |||
| Jensen Alpha | 0.802 | |||
| Total Risk Alpha | 0.3068 | |||
| Treynor Ratio | (3.40) | |||
| Maximum Drawdown | 35.71 | |||
| Skewness | 6.58 | |||
| Kurtosis | 45.22 |
Scancell Holdings plc Backtested Returns
Scancell Holdings appears to be out of control, given 3 months investment horizon. Scancell Holdings plc owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.13, which indicates the firm had a 0.13 % return per unit of risk over the last 3 months. By inspecting Scancell Holdings' technical indicators, you can evaluate if the expected return of 0.56% is justified by implied risk. Please review Scancell Holdings' Coefficient Of Variation of 607.64, risk adjusted performance of 0.1409, and Variance of 23.26 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Scancell Holdings holds a performance score of 9. The entity has a beta of -0.23, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Scancell Holdings are expected to decrease at a much lower rate. During the bear market, Scancell Holdings is likely to outperform the market. Please check Scancell Holdings' information ratio, as well as the relationship between the kurtosis and day typical price , to make a quick decision on whether Scancell Holdings' existing price patterns will revert.
Auto-correlation | 0.00 |
No correlation between past and present
Scancell Holdings plc has no correlation between past and present. Overlapping area represents the amount of predictability between Scancell Holdings time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Scancell Holdings plc price movement. The serial correlation of 0.0 indicates that just 0.0% of current Scancell Holdings price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Scancell Holdings plc reported net income of (2.06 Million). This is 100.61% lower than that of the Healthcare sector and 102.95% lower than that of the Biotechnology industry. The net income for all United States stocks is 100.36% higher than that of the company.
Scancell Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scancell Holdings' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Scancell Holdings could also be used in its relative valuation, which is a method of valuing Scancell Holdings by comparing valuation metrics of similar companies.Scancell Holdings is currently under evaluation in net income category among its peers.
Scancell Fundamentals
| Return On Equity | -0.44 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (1.60) % | |||
| Operating Margin | (2.06) % | |||
| Current Valuation | 239.16 M | |||
| Shares Outstanding | 818.4 M | |||
| Shares Owned By Insiders | 6.63 % | |||
| Shares Owned By Institutions | 49.22 % | |||
| Price To Earning | (8.00) X | |||
| Price To Book | 5.89 X | |||
| EBITDA | (146 K) | |||
| Net Income | (2.06 M) | |||
| Cash And Equivalents | 35.57 M | |||
| Cash Per Share | 0.04 X | |||
| Total Debt | 7.01 M | |||
| Debt To Equity | 0.35 % | |||
| Current Ratio | 24.05 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (10.19 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 40 | |||
| Beta | 0.48 | |||
| Market Capitalization | 435.14 M | |||
| Total Asset | 38.52 M | |||
| Z Score | 37.2 | |||
| Net Asset | 38.52 M |
About Scancell Holdings Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Scancell Holdings plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scancell Holdings using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scancell Holdings plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Scancell Pink Sheet
Scancell Holdings financial ratios help investors to determine whether Scancell Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Scancell with respect to the benefits of owning Scancell Holdings security.